EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Reduced vaccine-induced germinal center outputs in patients with inflammatory bowel disease treated with anti-TNF biologics

Michelle W Cheung, Samantha Xu, Janna R Shapiro, Freda Qi, Melanie Delgado-Brand, Karen Colwill, Roya M Dayam, Ying Liu, Jenny D Lee, Joanne M Stempak, James M Rini, Vinod Chandran und 3 weitere

Journal of Clinical Investigation · 01.10.2025 · 135 (19)

DOI: 10.1172/jci192589 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Clinical Investigation, online erschienen am 29.07.2025. Verfasst von Michelle W Cheung und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Immunology, University of Toronto, Toronto, Ontario, Canada. Hauptthemen laut MEDLINE: Inflammatory Bowel Diseases, SARS-CoV-2, Germinal Center, COVID-19. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 74 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Canadian Institutes of Health Research, Canada Research Chairs, Juan and Stefania Speck.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND Anti-TNF biologics are widely used to treat patients with immune-mediated inflammatory diseases. In mouse models, the complete absence of TNF impairs germinal center (GC) responses. Less is known about the impact of anti-TNF therapy on specific immune responses in humans. Widespread vaccination against SARS-CoV-2 offered an unprecedented opportunity to investigate the effects of biological therapies on responses to specific immunization. Previous work demonstrated that patients with inflammatory bowel disease (IBD) who were treated with anti-TNF biologics exhibited decreased Spike-specific antibody responses compared with patients with IBD treated with anti-IL-12/23 or healthy controls, even after 4 doses of mRNA vaccine. METHODS Here we analyzed humoral responses to SARS-CoV-2 immunization using single-cell RNA-Sequencing and flow cytometry of Spike-specific memory B cells (MBC), as well as avidity measurements of plasma antibodies from patients with IBD treated with anti-TNF or anti-IL-12/23 and from people in the healthy control group. RESULTS We observed decreased somatic hypermutation in the B cell receptors of Spike-specific MBCs and decreased antigen-specific MBC accumulation following SARS-CoV-2 mRNA vaccination in patients with IBD treated with anti-TNF, compared with patients with IBD treated with anti-IL-12/23 or people in the healthy control group. This decreased somatic hypermutation in Spike-specific MBCs in patients treated with anti-TNF correlated with decreased and delayed antibody affinity maturation and reduced neutralization activity. CONCLUSION These data provide in vivo evidence that anti-TNF, but not anti-IL-12/23, therapy impairs the quantity and quality of antigen-specific GC outputs in humans. FUNDING Juan and Stefania Speck (donation) and by Canadian Institutes of Health Research (CIHR)/COVID-Immunity Task Force (CITF) grants VR-1 172711, VS1-175545, GA2-177716, GA1-177703 and CIHR FDN 143301 &143350.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Inflammatory Bowel DiseasesSARS-CoV-2Germinal CenterCOVID-19COVID-19 VaccinesTumor Necrosis Factor-alphaTumor Necrosis Factor InhibitorsHumansFemaleAdultMaleMiddle AgedAntibodies, ViralSpike Glycoprotein, CoronavirusMemory B Cells

Stichwörter der Autor:innen

Adaptive immunityImmunologyInfectious diseaseVaccines

Substanzen

COVID-19 VaccinesAntibodies, ViralTumor Necrosis Factor-alphaTumor Necrosis Factor InhibitorsSpike Glycoprotein, Coronavirusspike protein, SARS-CoV-2

Autor:innen und Institutionen

  • Department of Immunology, University of Toronto, Toronto, Ontario, Canada.
  • Lunenfeld-Tanenbaum Research Institute at Mount Sinai Hospital, Sinai Health System, Toronto, Ontario, Canada.
  • Department of Molecular Genetics, University of Toronto, Toronto, Ontario, Canada.
  • Zane Cohen Centre for Digestive Diseases, Division of Gastroenterology, Mount Sinai Hospital, Sinai Health System, Toronto, Ontario, Canada.
  • Department of Biochemistry, University of Toronto, Toronto, Ontario, Canada.
  • Gladman Krembil Psoriatic Arthritis Research Program, Schroeder Arthritis Institute, Krembil Research Institute, University Health Network, Toronto, Ontario, Canada.

Förderung

  • Canadian Institutes of Health Research
  • Canada Research Chairs
  • Juan and Stefania Speck

Zitieren

APA

Cheung, M. W., Xu, S., Shapiro, J. R., Qi, F., Delgado-Brand, M., Colwill, K., Dayam, R. M., Liu, Y., Lee, J. D., Stempak, J. M., Rini, J. M., Chandran, V., Silverberg, M. S., Gingras, A. C., & Watts, T. H. (2025). Reduced vaccine-induced germinal center outputs in patients with inflammatory bowel disease treated with anti-TNF biologics. Journal of Clinical Investigation, 135(19). https://doi.org/10.1172/jci192589

Vancouver

Cheung MW, Xu S, Shapiro JR, Qi F, Delgado-Brand M, Colwill K, et al. Reduced vaccine-induced germinal center outputs in patients with inflammatory bowel disease treated with anti-TNF biologics. Journal of Clinical Investigation. 2025;135(19). doi:10.1172/jci192589

BibTeX
@article{Cheung2025,
  author = {Cheung, Michelle W and Xu, Samantha and Shapiro, Janna R and Qi, Freda and Delgado-Brand, Melanie and Colwill, Karen and Dayam, Roya M and Liu, Ying and Lee, Jenny D and Stempak, Joanne M and Rini, James M and Chandran, Vinod and Silverberg, Mark S and Gingras, Anne-Claude and Watts, Tania H},
  title = {Reduced vaccine-induced germinal center outputs in patients with inflammatory bowel disease treated with anti-TNF biologics},
  journal = {Journal of Clinical Investigation},
  year = {2025},
  volume = {135},
  number = {19},
  doi = {10.1172/jci192589}
}
Kostenlos starten →